Dare Bioscience (DARE) Misses Q2 EPS by 45c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Dare Bioscience (DARE) PT Lowered to $11 at Brookline Capital Markets
August 18, 2025 3:59 PM EDTBrookline Capital Markets analyst Kemp Dolliver lowered the price target on Dare Bioscience (NASDAQ: DARE) to $11.00 (from $14.00) while maintaining a Buy rating.
The analyst comments "Darés Q2 update was less informative than we expected. The company continues with plans to bring Sildenafil... More
